- Thermo Fisher Scientific has opened a new Advanced Therapies Collaboration Center in Philadelphia to support the development and commercialisation of cell and gene therapies.
- The site serves as the company’s East Coast flagship ATxCC and provides startups and biopharma organisations with access to scientists, process development technologies and collaboration opportunities.
Thermo Fisher Scientific has opened a new Advanced Therapies Collaboration Center (ATxCC) in Philadelphia. The centre is intended to support biopharma, biotech and translational researchers in advancing cell and gene therapy programmes from early development through to commercialisation.
The Philadelphia site is the company’s flagship East Coast ATxCC and its second U.S. location, following the opening of a centre in Carlsbad, California in April 2025. Thermo Fisher stated that the facility expands its national and international ATxCC network, which also includes sites in Korea and Singapore. The new centre is situated within the 53,000-square-foot BioLabs for Advanced Therapeutics Philadelphia.
According to the announcement, the centre will give emerging companies access to Thermo Fisher scientists, advanced process development tools and opportunities for collaboration. “Our new Advanced Therapies Collaboration Center in Philadelphia is designed to help innovators overcome critical hurdles in developing cell and gene therapies,” said Nicole Brockway, president of biosciences at Thermo Fisher.
BioLabs said embedding the ATxCC within its community provides startups with access to high-end technologies. Johannes Fruehauf, founder and CEO of BioLabs, stated that the centre will offer resources to both BioLabs members and external biotechs across the East Coast.
Thermo Fisher noted that cell and gene therapies remain a major focus for industry innovation, offering potential treatment options for conditions previously considered untreatable. The company said the new facility is designed to support customers as they progress from laboratory development to clinical evaluation.
